Media room
Media Contact Information
Amy Rose: 908-423-6537
Press Release
May 4, 2010 - ZEGERID OTC® provides greater and faster acid control than Prevacid® 24HR according to head-to-head clinical study
WHITEHOUSE STATION, NJ, May 4, 2010 — Merck Consumer Care today announced results of a head-to-head clinical study showing that ZEGERID OTC® offers greater and faster acid control than Prevacid® 24HR. While acid control is an industry standard measure for acid-reducing drugs, greater and faster acid control does not imply greater and faster heartburn symptom relief. The goal of the study was to evaluate the speed and amount of acid reduction when the medications were at full effect, as measured on day seven, which is halfway through the recommended course of treatment. Both products are proton pump inhibitors (PPIs), a class of heartburn medication that works by deactivating acid pumps in the stomach.
Downloads:
Press Release
April 1, 2010 - ZEGERID OTC® Hits Store Shelves; Offers Only Patented Dual-Ingredient Option for 24 Hour Frequent Heartburn Relief without a Prescription
WHITEHOUSE STATION, NJ, April 1, 2010 - Merck & Co., Inc. announced that beginning today, ZEGERID OTC® (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), a new over-the-counter (OTC) option for treating frequent heartburn without a prescription, will become available in drug stores, grocery stores, mass merchandisers and club stores nationwide. The only OTC proton pump inhibitor (PPI) product with two active ingredients, ZEGERID OTC delivers relief in a different way. ZEGERID OTC has a patented dual-ingredient formula that combines omeprazole, the leading prescription acid-reducing medicine, and sodium bicarbonate, which protects the omeprazole in this product from acid in the stomach and allows it to be absorbed. Read more...
Downloads:
Press Release
December 2, 2009- FDA Approves Zegerid OTC® for over-the-counter treatment of frequent heartburn
WHITEHOUSE STATION, NJ, December 2, 2009 — Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC® (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of frequent heartburn. ZEGERID OTC will be marketed over-the-counter by Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.
